← Human Trials & Peer-Reviewed Studies
Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field
Plain-language guide to PMID 39985668 (2025): randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 336 patients.
Key Facts
- PMID
- 39985668
- Journal
- Aging clinical and experimental research
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Xuan M et al. (8 authors)
- DOI
- 10.1007/s40520-025-02932-w
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.
This study aimed to investigate the effect of electromagnetic field (EMF) combined with recombinant human parathyroid hormone (rhPTH) on bone mineral density (BMD) and bone turnover indicators in postmenopausal osteoporosis (PMOP) patients.
Who Took Part
The abstract describes 336 patients taking part.
By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.
A total of 336 PMOP patients were randomly assigned into three groups: EMF + rhPTH group (n = 115), rhPTHx group (n = 113) and EMF group (n = 108).
The lumbar spine and femoral neck BMDs were measured before treatment and at 6, 12, and 18 months after treatment.
How the Study Was Run
The design is described as randomized.
The patients were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.
Blood calcium, bone alkaline phosphatase (BSAP), type I procollagen N-terminal peptide (PINP), and type I collagen C-terminal peptide/creatinine ratio (CTX/Cr) levels were measured before treatment and at 3, 6, 12, and 18 months after treatment.
What Was Measured
Topics PubMed links to this paper include Osteoporosis, Postmenopausal, Bone Density, Parathyroid Hormone, Calcium, Lumbar Vertebrae, Recombinant Proteins and Electromagnetic Fields.
Author keywords: Postmenopausal osteoporosis and Recombinant human parathyroid hormone.
What This Means in Plain Language
The paper is a randomized study of Parathyroid Hormone (PTH 1-84) in 336 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2025 (Aging clinical and experimental research), a journal based in Germany.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.